Horizon was founded by Dr Chris Torrance and Professor Alberto Bardelli and builds upon a 20 year heritage in oncology research, translational medicine and genome-editing.
The company is a trusted supplier of genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to almost 800 organizations engaged in bio-pharmaceutical process optimization; drug discovery & development and clinical diagnostic development.
Under the guidance of Chief Executive Officer, Dr Darrin M Disley since September 2007, the company has made strong commercial progress to become one of the UK’s fastest growing biotechnology companies.1
The Company has attracted a high-quality investor base including DFJ Esprit LLP, Genentech Incorporated, Roche Venture Fund AG, Hargreave Hale, Henderson Global Investors, Henderson Volantis, Invesco Asset Management Ltd, Legal & General Investment Management Ltd, Odey Asset Management LLP, and Dr Jonathan Milner.
Over 300 publications relating to the use of rAAV, GENESIS™, X-MAN™ cell lines and applications thereof have been published in peer-reviewed journals such as Science, Nature, Nature Biotechnology, PNAS, Cancer Cell, Cancer Research, The Journal of American Medical Association and The Journal of Clinical Oncology by Horizon founders, scientific advisers, Center of Excellence sites and research collaborators. The abstracts for these publications can be found in the reference library section of this website.
The company is part of five multi-national grant-funded translational research consortia, is a partner in over 100 academic research collaborations and has established over 30 human gene-editing Centers of Excellence including the US National Institutes of Health (NCI & NHGRI).
Horizon holds a secure intellectual property position in virally-mediated gene-editing with a patent estate comprising 16 granted patents underpinning the GENESIS™ platform itself. In addition, there are 26 pending patent applications claiming improvements to the platform that reflect the ten-fold improvement in gene targeting efficiency developed by Horizon in the course of industrialization of the platform in 2011-12.
Through the Centers of Excellence program, Horizon allows academic researchers to access our secure IP position in rAAV gene-editing, our nuclease technologies, and our human isogenic disease models for the development of novel cell lines. This open innovation approach has already allowed the creation of additional intellectual property and product pipelines.
1 Deloitte Fast 50 2013, Horizon ranked 1st in the Biotechnology category
Paragraph explaining benefits of Biocair×